EU approves Avastin + chemotherapy for recurrent Ovarian Cancer - Roche
Roche announced that the European Commission (EU) approved the use of Avastin (bevacizumab) in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin chemotherapy as a treatment for women with recurrent Ovarian Cancer that is resistant to platinum-containing chemotherapy.
The EU approval was based on results of the phase III AURELIA study which involved women with recurrent, platinum-resistant Ovarian Cancer who received either chemotherapy or Avastin in combination with chemotherapy. Results showed that the addition of Avastin to chemotherapy gave a clinically meaningful benefit, nearly doubling the median progression free survival (PFS) from 3.4 months to 6.7 months (HR=0.38, p<0.0001).>
In 2011, Avastin was approved in the EU as a front-line treatment for advanced Ovarian Cancer based on the pivotal GOG 0128 and ICON7 phase III studies. In 2012, Avastin was approved in the EU as a treatment for recurrent, platinum-sensitive Ovarian Cancer based on the results of the pivotal phase III OCEANS study.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.